MENU
+Compare
GRFS
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$10.13
Change
+$0.23 (+2.32%)
Capitalization
8.66B

GRFS stock forecast, quote, news & analysis

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more

GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GRFS showed earnings on July 29, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for GRFS with price predictions
Sep 05, 2025

GRFS's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for GRFS moved out of overbought territory on August 15, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GRFS turned negative on August 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where GRFS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 05, 2025. You may want to consider a long position or call options on GRFS as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

GRFS moved above its 50-day moving average on September 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

GRFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 189 cases where GRFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.144) is normal, around the industry mean (9.484). P/E Ratio (19.746) is within average values for comparable stocks, (24.036). Projected Growth (PEG Ratio) (0.195) is also within normal values, averaging (1.781). Dividend Yield (0.017) settles around the average of (0.028) among similar stocks. GRFS's P/S Ratio (0.767) is slightly lower than the industry average of (3.470).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GRFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

A.I.Advisor
published Dividends

GRFS paid dividends on August 20, 2025

Grifols SA GRFS Stock Dividends
А dividend of $0.18 per share was paid with a record date of August 20, 2025, and an ex-dividend date of August 12, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 90.31B. The market cap for tickers in the group ranges from 72.83K to 651.91B. LLY holds the highest valuation in this group at 651.91B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 10%. SCLX experienced the highest price growth at 28%, while PTKFF experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 18%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 70
Price Growth Rating: 55
SMR Rating: 61
Profit Risk Rating: 79
Seasonality Score: -35 (-100 ... +100)
View a ticker or compare two or three
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of plasma-derived biological medicines

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Avinguda de la Generalitat, 152
Phone
+34 935712200
Employees
23744
Web
https://www.grifols.com